Tirzepatide emerges a groundbreaking pharmaceutical agent for individuals facing type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://polaris-peptide.com/product/tirzepatide-50mg/